AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05095259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle biopsy
Description: With the study subject resting in the supine position, the skin is disinfected on the lateral side of the thigh around 15 cm above the knee, with chlorhexidine alcohol. Then 3-4 mL of local anaesthetic (lidocaine 20 mg/mL) is injected into the skin, subcutaneous tissue and in the upper part of the muscle with a very thin needle. When the anaesthetic effect has set in after a couple of minutes an insertion is made in the skin and the subcutaneous tissue through which the biopsy cannula is inserted into the muscle. A small piece (around 150 mg) of the muscle is collected, which may be experienced as somewhat unpleasant, but will last for a very short while ( \~1-2 seconds). The needle is removed, a sterile Band-Aid is applied, and the study subject can leave the site after termination of the trial. The biopsy may cause some muscular tenderness for 2-3 days corresponding to minor muscular trauma.
Study NCT05095259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Description: With the study subject resting in the supine position, the skin is disinfected on the lateral side of the thigh around 15 cm above the knee, with chlorhexidine alcohol. Then 3-4 mL of local anaesthetic (lidocaine 20 mg/mL) is injected into the skin, subcutaneous tissue and in the upper part of the muscle with a very thin needle. When the anaesthetic effect has set in after a couple of minutes an insertion is made in the skin and the subcutaneous tissue through which the biopsy cannula is inserted into the muscle. A small piece (around 150 mg) of the muscle is collected, which may be experienced as somewhat unpleasant, but will last for a very short while ( \~1-2 seconds). The needle is removed, a sterile Band-Aid is applied, and the study subject can leave the site after termination of the trial. The biopsy may cause some muscular tenderness for 2-3 days corresponding to minor muscular trauma.
Study NCT05095259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adipose tissue biopsy
Description: With the study subject resting in the supine position, the skin is disinfected on one side of the abdomen around 5-10 cm lateral from the umbilicus to the knee, with chlorhexidine alcohol. Then 3-4 mL of local anaesthetic (lidocaine 20 mg/mL) is injected into the skin, subcutaneous tissue and in the upper part of the adipose tissue with a very thin needle. When the anaesthetic effect has set in after a couple of minutes an insertion is made in the skin and the subcutaneous tissue through which the biopsy cannula is inserted into the adipose tissue. A small piece (around 1 gram) of the adipose tissue is collected, which may be experienced as somewhat unpleasant, but will last for a very short while ( \~1-2 seconds). The needle is removed, a sterile Band-Aid is applied, and the study subject can leave the site after termination of the trial. The biopsy may cause some tenderness for 2-3 days corresponding to minor trauma.
Study NCT05095259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose tissue biopsy
Description: With the study subject resting in the supine position, the skin is disinfected on one side of the abdomen around 5-10 cm lateral from the umbilicus to the knee, with chlorhexidine alcohol. Then 3-4 mL of local anaesthetic (lidocaine 20 mg/mL) is injected into the skin, subcutaneous tissue and in the upper part of the adipose tissue with a very thin needle. When the anaesthetic effect has set in after a couple of minutes an insertion is made in the skin and the subcutaneous tissue through which the biopsy cannula is inserted into the adipose tissue. A small piece (around 1 gram) of the adipose tissue is collected, which may be experienced as somewhat unpleasant, but will last for a very short while ( \~1-2 seconds). The needle is removed, a sterile Band-Aid is applied, and the study subject can leave the site after termination of the trial. The biopsy may cause some tenderness for 2-3 days corresponding to minor trauma.
Study NCT05095259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon is prepared in doses of 10 µg, 25 µg, and 50 µg and intravenously injected with intervals of 2 hours. After each glucagon injection, blood samples will be drawn to measure plasma glucose, glucagon, lactate, free fatty acids, alanine, amino-acids, β-hydroxybutyrate, glycerol and insulin. Furthermore, cardiovascular measurements such as pulse and blood pressure are monitored as well.
Study NCT05095259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon is prepared in doses of 10 µg, 25 µg, and 50 µg and intravenously injected with intervals of 2 hours. After each glucagon injection, blood samples will be drawn to measure plasma glucose, glucagon, lactate, free fatty acids, alanine, amino-acids, β-hydroxybutyrate, glycerol and insulin. Furthermore, cardiovascular measurements such as pulse and blood pressure are monitored as well.
Study NCT05095259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IPRO 2 Medtronic Minimed
Description: All potential subjects will receive a blinded continuous glucose sensor at Visit 1. At the following visits, the continuous glucose monitor (CGM) will be reviewed for hypoglycaemia episodes and replaced at the same time. At Visit 2 a final screening of the inclusion criteria will take place, which involves the CGM data of the first week. A blinded CGM will be installed a week before every visit.
Study NCT05095259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPRO 2 Medtronic Minimed
Description: All potential subjects will receive a blinded continuous glucose sensor at Visit 1. At the following visits, the continuous glucose monitor (CGM) will be reviewed for hypoglycaemia episodes and replaced at the same time. At Visit 2 a final screening of the inclusion criteria will take place, which involves the CGM data of the first week. A blinded CGM will be installed a week before every visit.
Study NCT05095259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 7 Tesla (7T) Magnetic Resonance Imaging
Description: Subjects will undergo a hyperinsulinemic euglycaemic glucose clamp, as mentioned above, in the MRI scanning room. After 30 minutes of stable normoglycaemia, subjects are taken into the MRI scanner (Philips Achieva 7.0 T) where brain, liver, thigh and calf muscle are scanned. After every anatomically different area, the subjects must be taken out of the scanner, while scanning coils are replaced. All subjects are advised to lie still and press the alarm button if necessary.
Study NCT05095259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 7 Tesla (7T) Magnetic Resonance Imaging
Description: Subjects will undergo a hyperinsulinemic euglycaemic glucose clamp, as mentioned above, in the MRI scanning room. After 30 minutes of stable normoglycaemia, subjects are taken into the MRI scanner (Philips Achieva 7.0 T) where brain, liver, thigh and calf muscle are scanned. After every anatomically different area, the subjects must be taken out of the scanner, while scanning coils are replaced. All subjects are advised to lie still and press the alarm button if necessary.
Study NCT05095259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect Calorimetry using Jaeger Oxycon Champion
Description: Resting metabolic rate will be estimated, after reaching stable plasma glucose level, via a hyperinsulinemic euglycaemic clamp, as mentioned above. This will be done by indirect calorimetry, using a ventilated hood system (Jaeger Oxycon Champion, software version 4.3, Jaeger, Mijnhardt). Subjects are instructed to lie down and rest for a period of 30 minutes. Subjects are also instructed not to move, talk or sleep unless necessary during the period of measurement. The recorded measurement after 5 minutes to 30 minutes will be used for analysis.
Study NCT05095259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect Calorimetry using Jaeger Oxycon Champion
Description: Resting metabolic rate will be estimated, after reaching stable plasma glucose level, via a hyperinsulinemic euglycaemic clamp, as mentioned above. This will be done by indirect calorimetry, using a ventilated hood system (Jaeger Oxycon Champion, software version 4.3, Jaeger, Mijnhardt). Subjects are instructed to lie down and rest for a period of 30 minutes. Subjects are also instructed not to move, talk or sleep unless necessary during the period of measurement. The recorded measurement after 5 minutes to 30 minutes will be used for analysis.
Study NCT05095259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Core temperature and thermography using Thermovision SC645
Description: Thermography (Thermovision SC645, FLIR Systems, Wilsonville, OR, USA) is used to determine cutaneous vascular perfusion. Data is analogue-digital converted and sampled at 100 Hz (Powerlab, ADInstruments, Colorado Springs, CO, USA).
Study NCT05095259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core temperature and thermography using Thermovision SC645
Description: Thermography (Thermovision SC645, FLIR Systems, Wilsonville, OR, USA) is used to determine cutaneous vascular perfusion. Data is analogue-digital converted and sampled at 100 Hz (Powerlab, ADInstruments, Colorado Springs, CO, USA).
Study NCT05095259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freestyle Libre 2
Description: All potential subjects will receive a continuous glucose sensor at Visit 1. At the following visits, the CGM will be reviewed for hypoglycaemia episodes and replaced at the same time. At Visit 2 a final screening of the inclusion criteria will take place, which involves the CGM data of the first week. A CGM will be installed a week before every visit.
Study NCT02016079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3
Description: 200 ml fruit drink containing omega-3
Study NCT03113994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin Calcium
Description: 10mg Rosuvastatin, daily for 12 months
Study NCT03113994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo, daily for 12 months
Study NCT03113994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Coenzyme Q10
Description: 100mg CoQ10, daily for 12 months
Study NCT04265417 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic Assisted Rectal Cancer Resection With Natural Orifice Specimen Extraction
Description: participants in this group underwent robotic rectal cancer resection，the specimens were extractd through anus and vagina.
Study NCT00022399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: 400mg PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
Study NCT00022399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
Study NCT03113994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: 100mg CoQ10, daily for 12 months
Study NCT03113994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate
Description: 1250mg Calcium Carbonate, daily for 12 months
Study NCT03113994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: 1250mg Calcium Carbonate, daily for 12 months
Study NCT03113994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: 2000IU Vitamin D, daily for 12 months
Study NCT03113994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 2000IU Vitamin D, daily for 12 months
Study NCT02934724 — intervention group
Intervention type: PROCEDURE
Intervention: Self sample from vagina
Description: Self sample using The Rover's Evalyn Brush
Study NCT02934724 — intervention group
Intervention type: PROCEDURE
Intervention: Self sample from the oral cavity
Description: Self sample using COPAN FloqSwab
Study NCT02934724 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire about vaccination status and sexual behaviour
Study NCT03495882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1884 + AGEN2034
Description: AGEN1884 + AGEN2034 according to protocol design
Study NCT00400647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated Mycophenolate sodium (EC-MPS)
Study NCT00400647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Study NCT03802448 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Study group
Description: Each pregnant woman in the study group received myofascial release technique, 3 sessions/week for 4 weeks. a myofascial release in addition to wearing a natural wrist splint during sleeping for 4 weeks.~Myofascial wrist retinaculum (Transverse carpal ligament) release.~• Second part; Interosseous membrane and forearm muscles myofascial release (Bilateral thumb pressure technique).
Study NCT00421928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Description: 10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks
Study NCT00421928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo twice a day (BID) during 15 weeks
Study NCT00421928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503)
Description: 50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks
Study NCT01024894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-7
Description: 3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week
Study NCT03802448 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping.
Study NCT03802448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control group
Description: A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping.
Study NCT00437684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: 200/50 mg 2 cpr bid monotherapy
Study NCT00437684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LPV/r
Description: 200/50 mg 2 cpr bid monotherapy
Study NCT00437684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFNa 2a
Description: PEG-IFNa 2a 180 mcg/week
Study NCT00437684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-IFNa 2a
Description: PEG-IFNa 2a 180 mcg/week
Study NCT01602822 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ritonavir, Atazanavir, Truvada
Study NCT02205463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD019
Study NCT02368964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist 0.2 mg + hCG 250 mcg
Description: Treatment for triggering
Study NCT02368964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose hCG 500 mcg
Description: Treatment for triggering
Study NCT00437684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 1-1.2 g/day
Study NCT00437684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin 1-1.2 g/day
Study NCT00437684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NUCS
Description: Nucleoside Reverse Transcriptase Inhibitors
Study NCT01537783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Scrubs applied once a day for 5 days
Study NCT01537783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin
Description: Nasal mupirocin applied topically to both nostrils twice a day for 5 days
Study NCT01408186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: Rabeprazole 20 mg daily
Study NCT01408186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Famotidine 40mg daily
Study NCT02888327 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AL-794
Study NCT02888327 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oseltamivir
Study NCT02888327 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Digoxin
Study NCT02888327 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Study NCT02888327 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pitavastatin
Study NCT02888327 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: JNJ-63623872
Study NCT03578744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Flap surgery
Description: After administering local anaesthetic a full thickness flap will be raised and reflected to expose the furcation defects. The furcation defects would then be debrided and the graft and membrane secured in position. Later the flap would be sutured back.
Study NCT03241641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: 25mg, Daily Oral
Study NCT03241641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Alafenamide
Description: 25mg, Daily Oral
Study NCT01701089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-L-deprenyl-D2
Description: Intravenous injection of 11C-L-deprenyl-D2 before positron emission tomography (PET); up to 3 injections in total
Study NCT03241641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: 300mg, Daily Oral
Study NCT03782168 — intervention group
Intervention type: OTHER
Intervention: There is no other intervention, only clinical treatment.
Description: The purpose of this study is to determine how well maternal serum biomarkers and placental micro-particles (MP) correlate with PA. The sensitivity and specificity of these proteins will be analyzed to further increase our understanding of the pathological mechanisms involved in PA.
Study NCT01753180 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collagenase
Description: Local intra-coronary administration of MZ-004 at or into the CTO
Study NCT01753180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Local intra-coronary administration of saline at or into the CTO
Study NCT02754050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem Snare
Study NCT00451204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estriol
Description: Estriol 8 mg capsule, once per day, duration of treatment is 2 years
Study NCT00451204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, once a day, treatment duration is 2 years
Study NCT00451204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copaxone
Description: Injection, once a day, all subjects
Study NCT00451204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Copaxone
Description: Injection, once a day, all subjects
Study NCT03923140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast
Description: 5mg/kg.d for juvenile patients with a maximum dose of 0.3g per day; 0.1g each time, three times a day for adults patients
Study NCT01480869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcium and cholecalciferol
Description: Tablet to suck: calcium 500 mg bid, cholecalciferol 200 IU bid
Study NCT01480869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium and cholecalciferol
Description: Tablet: calcium 500 mg bid + 2 ml drinkable solution cholecalciferol 100 000 IU whose schedule of administration depends on vitamin deficiency level:~* 100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25-OHD level \< 10 ng/mL~* 100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25-OHD level \< 20 ng/mL~* 100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25-OHD level \< 30 ng/mL
Study NCT01184495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa-BioManguinhos
Description: Subcutaneous administration of EPO-BioManguinhos
Study NCT02874469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diary
Description: The diary was specifically created for the purpose of the present study by personal working at ICU at CHRU of Lille (France).~All relatives, doctors and paramedics close to the patient during his hospital stay are allowed to write some comments inside the diary when he is comatose.~The diary will be implemented during the second period of the study within the first 8 hours after admission.~It will be given to the patients themselves at discharge or to their relatives in case of in-hospital death. An anonymous copy will be kept by investigators.
Study NCT01184495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa-BioSimilar
Description: Subcutaneous administration of EPO-BioSimilar
Study NCT01701089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4602522
Description: Multiple doses of RO4602522 for 14 days
Study NCT01701089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4602522
Description: Multiple doses of RO4602522 for up to 17 days
Study NCT04054245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXL2 Inhibitor PAT-1251
Description: Given PO
Study NCT04054245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04054245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies